Understanding the target

Michael R. Stratton () and P. Andrew Futreal ()
Additional contact information
Michael R. Stratton: Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus
P. Andrew Futreal: Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus

Nature, 2004, vol. 430, issue 6995, 30-30

Abstract: The complicated responses of lung-cancer patients to a particular drug — gefitinib — are now less puzzling. Mutations in the target gene help to explain why the treatment works in some cases but not in others.

Date: 2004
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/430030a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:430:y:2004:i:6995:d:10.1038_430030a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/430030a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().